Insider Trading March 27, 2026

Donaldson President Executes Option Exercise, Sells $1.75M in Stock

Guillermo Briseno both exercised options and sold shares as company reports a modest quarterly shortfall

By Derek Hwang DCI
Donaldson President Executes Option Exercise, Sells $1.75M in Stock
DCI

Donaldson Co President Guillermo Briseno sold 20,600 shares on March 26, 2026, for roughly $1.75 million and exercised options to acquire the same number of shares. The transactions leave him with 29,267 directly held shares as the company reports a fiscal Q2 2026 earnings miss and a reiterated Equalweight rating from Morgan Stanley.

Key Points

  • President Guillermo Briseno sold 20,600 shares on March 26, 2026, for approximately $1.75 million at $84.97 per share.
  • Briseno exercised options to acquire 20,600 shares in two tranches - 12,000 at $42.72 and 8,600 at $45.43 - valued at $903,338.
  • Donaldson reported fiscal Q2 2026 adjusted EPS of $0.83 and revenue of $896.3 million, both slightly below analyst expectations; Morgan Stanley reiterated an Equalweight rating with a $93 price target.

Donaldson Co INC (NYSE: DCI) President Guillermo Briseno completed a pair of related equity moves on March 26, 2026, combining an option exercise with an open-market sale that generated about $1.75 million in proceeds.

Briseno sold 20,600 shares of Donaldson common stock at $84.97 per share on March 26, 2026. That sale price was marginally higher than the stock's then-current trading level of $84.29. Independent InvestingPro analysis cited in company reporting shows the shares trading close to their Fair Value.

Concurrently, Briseno exercised options to acquire 20,600 shares of Donaldson common stock in two tranches. The first tranche covered 12,000 shares at an exercise price of $42.72 per share, and the second tranche covered 8,600 shares at $45.43 per share. The combined value of those option exercises is recorded at $903,338.

After accounting for the option exercises and the sales, Briseno's direct holdings in Donaldson total 29,267 shares.


On the company fundamentals side, research summaries cited by InvestingPro note a return on equity of 24% for Donaldson, and that the firm has increased its dividend for 30 consecutive years.

Those corporate metrics arrive against a backdrop of mixed near-term operating results. Donaldson reported fiscal second-quarter 2026 adjusted earnings per share of $0.83, which missed the consensus forecast of $0.89. Quarterly revenue came in at $896.3 million, narrowly below the anticipated $898.59 million. The shortfall on both EPS and revenue has drawn attention from investors assessing the firm's near-term performance.

Separately, Morgan Stanley maintained an Equalweight rating on Donaldson Company and set a price target of $93. The affirmation of the rating was issued by analyst Angel Castillo.

Taken together, the insider transactions, the company's stated fundamentals, and the recent quarterly results provide a concise update on executive activity and near-term performance for market participants tracking DCI. Investors seeking further, in-depth analysis can access Pro Research Reports that cover DCI and a broad universe of U.S. equities, as noted in the referenced InvestingPro materials.

Risks

  • Near-term operational risk reflected in fiscal Q2 2026 results, where adjusted EPS and revenue missed analyst forecasts - this may affect market sentiment for industrial and manufacturing sectors.
  • Insider selling following an option exercise could be interpreted variably by investors, potentially introducing volatility in the company's equity trading activity within capital markets.
  • Reliance on current valuation metrics - InvestingPro notes shares trade near Fair Value, limiting immediate upside if market conditions do not change.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026